Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis

PloS One
Dan QianBing Situ

Abstract

This study aimed to investigate the efficacy and safety of dual therapy comprising sulfonylurea (SU) plus antidiabetic drugs for the treatment of type 2 diabetes mellitus (T2DM). We searched the PubMed, Cochrane library, and Embase databases for randomized clinical trials (≥24 weeks) published up to December 28, 2017. Subsequently, we conducted pairwise and network meta-analyses to calculate the odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs) of the outcomes. The final analyses included 24 trials with a total of 10,032 patients. Compared with placebo, all treatment regimens were associated with a significantly higher risk of hypoglycemia, except the combinations of SU plus sodium-glucose co-transporter-2 inhibitor (SGLT-2i) [OR, 1.35 (95% CI: 0.81 to 2.25)] or alpha-glucosidase inhibitor (AGI) [OR, 1.16 (95% CI: 0.55 to 2.44)]. Notably, the combination of SU plus glucagon-like peptide-1 receptor agonist (GLP-1RA) was associated with the most significant increase in the risk of hypoglycemia. Furthermore, all SU-based combination regimens reduced the glycated hemoglobin (HbA1c) and fasting plasma glucose levels (FPG). However, only combinations containing SGLT-2i [MD, -1.00 kg (95% CI: -1.73 to -0...Continue Reading

References

Feb 26, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·B H WolffenbuttelR N Patwardhan
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Sep 28, 2004·Statistics in Medicine·G Lu, A E Ades
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Oct 15, 2005·BMJ : British Medical Journal·Deborah M CaldwellJ P T Higgins
Apr 25, 2006·Metabolism: Clinical and Experimental·Stefano Del Prato, Nicolò Pulizzi
May 31, 2007·Clinical Drug Investigation·Werner BachmannUNKNOWN European Acarbose Study Group
Dec 28, 2007·Diabetes Research and Clinical Practice·Jochen Seufert, Richard Urquhart
Oct 18, 2008·Diabetes, Obesity & Metabolism·A V Matveyenko, P C Butler
Mar 6, 2009·The American Journal of Gastroenterology·F KeusC J H M van Laarhoven
Oct 28, 2009·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Helena W RodbardStanley S Schwartz
Dec 17, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·A J ScheenUNKNOWN PROactive investigators
Mar 20, 2010·International Journal of Clinical Practice·A H BarnettA Middleton
Sep 1, 2011·Diabetes Research and Clinical Practice·Spyridon O Bakatselos
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Mar 20, 2012·Cell·Frances M Ashcroft, Patrik Rorsman
Mar 31, 2012·International Journal of Epidemiology·Rebecca M TurnerJulian Pt Higgins
Mar 20, 2013·International Journal of Epidemiology·Areti Angeliki VeronikiGeorgia Salanti
Aug 1, 2013·BMJ : British Medical Journal·Atsushi GotoMitsuhiko Noda
Oct 8, 2013·PloS One·Anna ChaimaniGeorgia Salanti
Feb 11, 2014·Diabetes Research and Clinical Practice
Feb 25, 2014·Current Diabetes Reports·Peter M Thulé, Guillermo Umpierrez
Mar 19, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeroen P JansenGeorgia Salanti
Oct 8, 2014·Nature Reviews. Endocrinology·Brian M Frier
Sep 8, 2015·Contemporary Clinical Trials·Rebecca DerSimonian, Nan Laird

❮ Previous
Next ❯

Citations

Apr 24, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Miao Yu
Mar 12, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Krzysztof StrojekIra Gantz

❮ Previous
Next ❯

Software Mentioned

Stata
Cochrane

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.